A study of ampreloxetine for neurogenic orthostatic hypotension in participants with multiple system atrophy (H-55684)

A phase 3, multi-center, randomized withdrawal and long-term extension study of ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension in participants with multiple system atrophy

The purpose of this study is to evaluate ampreloxetine in patients with Multiple System Atrophy.  Ampreloxetine is an investigational drug, which means that the FDA has not approved it for the treatment of Multiple System Atrophy or any other indication.

This study will look at whether an investigational drug, called ampreloxetine, works and how safe it is when taken over several months to treat symptomatic nOH in people with multiple system atrophy (MSA). It will also look at the effects of ampreloxetine on general well-being and if it can improve symptoms of nOH.